Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7412 p151
5 August 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Paracetamol continues to be sold in excess despite legislation restricting pack sizes

People are still finding it easy to purchase a large number of paracetamol tablets for use in suicide attempts, a study reveals (Postgraduate Medical Journal 2006;82:520).

Researchers from Guy’s and St Thomas’ Hospital, London, surveyed 107 individuals admitted to hospital for acute paracetamol overdose. They found that 46 per cent of those who intentionally purchased the drug to take an overdose had been able to purchase potentially toxic amounts greater than the pack sizes stipulated by legislation in 1998.

Only one patient had purchased an excessive amount from a pharmacy — all others had obtained paracetamol from non-pharmacy outlets.

The authors also tried to find out how many pharmacies would be prepared to sell more than the restricted amount; in four out of the eight pharmacies visited in south London, researchers were able to purchase at least 48 paracetamol tablets. The authors claim that, despite the small study size, their data suggest that legislation may not be achieving the goal of reducing the amount of paracetamol in households available for overdose.

Paul Dargan, medical toxicologist from the Guy’s and St Thomas’ Poisons Unit and co-author of the study, commented: “It is appropriate for pharmacists to have a brief discussion about the quantity of paracetamol that a customer is wishing to purchase, the maximum safe dosage and safe storage of the product.”

Robert Clayton, head of practice and quality improvement, Royal Pharmaceutical Society, said: “Although UK legislation restricts pack sizes, the law currently permits up to 100 paracetamol tablets to be sold [by pharmacists] at any one time.” He added that pharmacists are expected to use their professional judgement to determine whether this is appropriate on a case-by-case basis.

Back to Top


©The Pharmaceutical Journal